| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 12/05/2002 | WO2002096893A1 Process for preparing a thialzole ppar-ligand and polymorphs thereof |
| 12/05/2002 | WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient |
| 12/05/2002 | WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 12/05/2002 | WO2002096887A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 12/05/2002 | WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists |
| 12/05/2002 | WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 12/05/2002 | WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production |
| 12/05/2002 | WO2002096867A2 Inhibitors of protein kinase for the treatment of disease |
| 12/05/2002 | WO2002096866A2 Thiolalkyl benzoic acid derivatives |
| 12/05/2002 | WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments |
| 12/05/2002 | WO2002096863A1 New phenylalkyloxy-phenyl derivatives |
| 12/05/2002 | WO2002096858A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 12/05/2002 | WO2002096516A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 12/05/2002 | WO2002096465A1 Medicinal compositions for percutaneous absorption |
| 12/05/2002 | WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries |
| 12/05/2002 | WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin |
| 12/05/2002 | WO2002096441A1 Use of a product comprising catuama extract as an antioxidant and cerebral vasodilator agent |
| 12/05/2002 | WO2002096436A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis |
| 12/05/2002 | WO2002096428A1 Pharmaceutical combinations |
| 12/05/2002 | WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 12/05/2002 | WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 12/05/2002 | WO2002096421A1 5-substituted-2-arylpyridines as crf1 modulators |
| 12/05/2002 | WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
| 12/05/2002 | WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 12/05/2002 | WO2002096401A1 Solid pharmaceutical formulations comprising modafinil |
| 12/05/2002 | WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 12/05/2002 | WO2002096367A2 Targeted multivalent macromolecules |
| 12/05/2002 | WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
| 12/05/2002 | WO2002096363A2 Method for treating fibrotic diseases or other indications |
| 12/05/2002 | WO2002096362A2 Method for treating fibrotic diseases or other indications vi |
| 12/05/2002 | WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 12/05/2002 | WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | WO2002081415A3 Method for inhibiting metap2 |
| 12/05/2002 | WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| 12/05/2002 | WO2002070557A3 Nuclear hormone receptor ligand binding domain |
| 12/05/2002 | WO2002066450A3 Anthrone derivatives and their use as ink inhibitors |
| 12/05/2002 | WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same |
| 12/05/2002 | WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 12/05/2002 | WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 12/05/2002 | WO2002059155A3 Modulation of calcium channel activity |
| 12/05/2002 | WO2002042321A3 Mixed fibrils |
| 12/05/2002 | WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 12/05/2002 | WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof |
| 12/05/2002 | WO2002009685A1 Preparation with vascular protective and anti-oxidative effect and use thereof |
| 12/05/2002 | WO2002006453A3 Regulation of human desc1-like serine protease |
| 12/05/2002 | WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/05/2002 | WO2001093840A2 Ligands of integrin receptors |
| 12/05/2002 | WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis |
| 12/05/2002 | WO2001090142A3 FULL LENGTH HUMAN HCN1 Ih CHANNEL SUBUNIT AND VARIANTS |
| 12/05/2002 | WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 12/05/2002 | US20020183764 Embolic materials |
| 12/05/2002 | US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 12/05/2002 | US20020183515 Asymmetric synthesis of a key intermediate for making benazepril and analogues thereof |
| 12/05/2002 | US20020183507 Novel human GABA receptor proteins and polynucleotides encoding the same |
| 12/05/2002 | US20020183399 Method and compositions for treating rosacea |
| 12/05/2002 | US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders |
| 12/05/2002 | US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B) |
| 12/05/2002 | US20020183381 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF |
| 12/05/2002 | US20020183378 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 12/05/2002 | US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms |
| 12/05/2002 | US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis |
| 12/05/2002 | US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| 12/05/2002 | US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond |
| 12/05/2002 | US20020183352 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole |
| 12/05/2002 | US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea |
| 12/05/2002 | US20020183338 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 12/05/2002 | US20020183334 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder |
| 12/05/2002 | US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy |
| 12/05/2002 | US20020183321 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 12/05/2002 | US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer |
| 12/05/2002 | US20020183309 For therapy of acute myocardial infarction, asthma, bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, cutaneous carcinoma, drug abuse, depression, gastrointestinal disorders, inflammation |
| 12/05/2002 | US20020183305 For therapy of hyperlipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals |
| 12/05/2002 | US20020183300 Zinc ionophores as anti-stress agents |
| 12/05/2002 | US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient |
| 12/05/2002 | US20020183269 Novel compounds |
| 12/05/2002 | US20020183263 Nutritional preparation comprising ribose and medical use thereof |
| 12/05/2002 | US20020183260 For therapy of cardiovascular disorders in mammals; for inhibiting both angiotensin converting enzyme and neutral endopeptidase in mammals |
| 12/05/2002 | US20020183253 Effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with ocular neovascularization to an ocular neovascularization inhibiting effective amount |
| 12/05/2002 | US20020183244 Coating endoluminal surface of a tissue by coating with water soluble proteinaceous material and with di- or polyaldehyde; allowing formulation to cure |
| 12/05/2002 | US20020182683 Vascular endothelial growth factor 2 |
| 12/05/2002 | US20020182655 Method for identifying ligands for G protein-coupled receptors |
| 12/05/2002 | US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect |
| 12/05/2002 | US20020182587 Detection of modulators of cell proliferation; obtain cells, monitor cell proliferation, incubate cell with modulator, detect adjustment in cell proliferation |
| 12/05/2002 | US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 12/05/2002 | US20020182265 Lubricious coatings for substrates |
| 12/05/2002 | US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. |
| 12/05/2002 | US20020182213 Method for the treatment of fibrosis |
| 12/05/2002 | US20020182147 Vitronectin receptor antagonist pharmaceuticals |
| 12/05/2002 | DE10127041A1 New glycine N-(1-biphenyl-4-yl-2-substituted-ethyl)-amides, are integrin receptor inhibitors useful for treating e.g. angiogenic, cardiovascular, inflammatory and osteolytic or tumor diseases |
| 12/05/2002 | DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases |
| 12/05/2002 | CA2449245A1 Small molecule antagonists of bcl2 family proteins |
| 12/05/2002 | CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 12/05/2002 | CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 12/05/2002 | CA2449056A1 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| 12/05/2002 | CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2448894A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 12/05/2002 | CA2448645A1 New phenylalkyloxy-phenyl derivatives |
| 12/05/2002 | CA2448639A1 Novel heterocyclic derivatives and medicinal use thereof |